News / Korea / yonhap_finance
DB Asset Management Launches Active ETF Focused on Innovative Drug Developers
Health Technology · Biotechnology · yonhap_finance · 2026-09-01
DB Asset Management has listed a new active ETF targeting promising South Korean companies specializing in innovative drug development and pipelines.
What Happened
New ETF Launch: DB Asset Management has officially listed the 'DB Mighty New Drug Focus Bio Active' ETF, which targets promising companies in the Korean healthcare sector. The fund utilizes an active management strategy to select stocks based on their drug development achievements and pipeline competitiveness.
Investment Strategy: The ETF focuses on two main pillars: First-In-Class (FIC) drugs that introduce new treatment paradigms and Best-In-Class (BIC) drugs that offer superior efficacy, safety, or convenience compared to existing therapies. This approach allows for diversified exposure to high-potential biotech firms.
Portfolio Expansion: With this launch, the firm has expanded its healthcare lineup to cover the entire spectrum of the industry, including biosimilars and CDMOs. The company noted that domestic drug development capabilities have been consistently validated through recent global clinical successes and technology exports.
Market Outlook: Management emphasized that the recent stock price corrections in the biotech sector should be viewed separately from the fundamental progress of drug development. They believe the current lower valuations present an ideal opportunity to selectively invest in companies with high-quality drug pipelines.